Accumulation in Tumor Tissue of Adoptively Transferred T Cells: A Comparison Between Intravenous and Intraperitoneal Injection
- 1 May 2006
- journal article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 29 (3) , 241-249
- https://doi.org/10.1097/01.cji.0000203078.97493.c3
Abstract
Accumulation of T cells at the tumor is essential in cancer immunotherapy based on adoptive transfer of tumor-specific T cells. To gain further insight into the accumulation process and to evaluate the effect of using different routes of cell transfer, we investigated the accumulation of ovalbumin-specific CD8+ T cells (OT-I) injected either intravenously (IV) or intraperitoneally (IP) into mice carrying a subcutaneous tumor of the ovalbumin-expressing melanoma cell line B16-OVA. Maximal accumulation of the adoptively transferred cells in tumor tissue was observed 5 days after injection, irrespective of the injection route. The route of injection affected neither the total number of adoptively transferred cells found in tumor tissue nor the kinetics of this accumulation. In the spleen, however, the accumulation of adoptively transferred cells was clearly dependent on the injection route. IP injections resulted in a large number of adoptively transferred cells in the spleen on all days analyzed. In comparison, IV injection resulted in significantly fewer adoptively transferred cells in the spleen, and this number decreased over time. The route of injection affected neither the activation status of the adoptively transferred T cells that accumulated at the tumor site, nor the ability of these cells to control tumor growth. Two cell populations, SIINFEKL-tetramer(Low)(Tet(Low))CD69+ CD25+ and Tet(high)CD69- CD25-, were present in tumor samples, whereas only Tet(High)CD69- CD25- cells accumulated in the spleen. In tumors, IV injection resulted in a higher fraction of adoptively transferred cells with an activated phenotype (Tet(Low)CD69+ CD25+) compared with IP injection.Keywords
This publication has 20 references indexed in Scilit:
- The Emergence of Modern Cancer ImmunotherapyAnnals of Surgical Oncology, 2005
- Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapyTrends in Immunology, 2005
- The α vβ 3 integrin as a tumor homing ligand for lymphocytesEuropean Journal of Immunology, 2004
- Current developments of immunotherapy in the clinicCurrent Opinion in Immunology, 2004
- Adoptive-cell-transfer therapy for the treatment of patients with cancerNature Reviews Cancer, 2003
- Visualizing the course of antigen‐specific CD8 and CD4 T cell responses to a growing tumorEuropean Journal of Immunology, 2003
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002
- Tumours can act as adjuvants for humoral immunityImmunology, 2001
- T cell receptor antagonist peptides induce positive selectionCell, 1994
- Tolerance of T-cell clones is associated with membrane antigen changesNature, 1983